Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bioavailability Enhancement: Drug Solubility Enhancement

Bioavailability Enhancement: Drug Solubility Enhancement

Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Bioavailability Enhancement: Drug Permeability Enhancement

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are employed to...

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Herbosomal nanocarriers using natural-origin surfactants: a quercetin-based strategy for Alzheimer's disease and oxidative-stress-driven neurodegeneration.

Scientific reports·2026

Same author

A novel antibacterial approach: targeting methicillin-resistant Staphylococcus aureus with carvone nanoemulgel.

Applied microbiology and biotechnology·2025

Same author

Improved oral bioavailability of paclitaxel through folate-engineered zein nanoparticles: Evaluation in intestinal organoid and in vivo models.

International journal of biological macromolecules·2025

Same author

Improved Photodynamic Therapy of Hepatocellular Carcinoma via Surface-Modified Protein Nanoparticles.

Pharmaceutics·2025

Same author

Gliclazide loaded spanlastic nanovesicles: empowering bioavailability and antidiabetic efficacy.

Drug development and industrial pharmacy·2025

Same author

Green HPLC method for determination of paracetamol and ibuprofen in human plasma: applications to pharmacokinetics.

Bioanalysis·2024

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Rosuvastatin-Metformin Co-Processing: Enhanced Dissolution, Oral Bioavailability, and Therapeutic Efficacy through a

Soha M El-Masry¹, Shaimaa K Mostafa², Shaimaa M Khedr³

¹Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour, P.O. Box 22516, Egypt.

Drug Development and Industrial Pharmacy

|July 15, 2026

Summary

This study developed a novel co-processed fixed-dose combination of rosuvastatin (ROS) and metformin (MET) using a solvent-minimized wet co-grinding method. The enhanced formulation significantly improved ROS dissolution, bioavailability, and anti-hyperlipidemic efficacy, offering a promising treatment for dyslipidemia and type 2 diabetes.

Keywords:

Metformin Rosuvastatin dissolution rate dyslipidemia pharmacokinetics wet co-grinding

More Related Videos

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Related Experiment Videos

Last Updated: Jul 16, 2026

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Area of Science:

Pharmaceutical Sciences
Drug Delivery Systems
Biopharmaceutics

Background:

Rosuvastatin calcium (ROS) exhibits poor aqueous solubility, limiting its oral absorption and therapeutic effectiveness.
Developing fixed-dose combinations (FDCs) for managing comorbid conditions like dyslipidemia and type 2 diabetes is clinically relevant.

Purpose of the Study:

To develop an oral co-processed fixed-dose combination of rosuvastatin (ROS) and metformin hydrochloride (MET) to enhance ROS dissolution and oral bioavailability.
To evaluate the biopharmaceutical performance and therapeutic efficacy of the co-processed ROS/MET system.

Main Methods:

Co-processed ROS/MET systems were prepared using a solvent-minimized wet co-processing approach.
Formulations were characterized using FTIR, PXRD, DSC/TGA, and SEM.
In vitro dissolution, in vivo pharmacokinetic studies in rats, and anti-hyperlipidemic efficacy assessments were conducted.

Main Results:

The co-processed ROS/MET formulation (F2) significantly enhanced rosuvastatin dissolution across various pH conditions compared to unprocessed ROS.
Pharmacokinetic studies showed a 21.5% increase in relative bioavailability and a 1.34-fold increase in Cmax for co-processed ROS.
The co-processed formulation demonstrated improved liver drug distribution and superior anti-hyperlipidemic effects in hyperlipidemic rats.

Conclusions:

Co-processing rosuvastatin with metformin via a solvent-minimized wet co-grinding method is an effective strategy to improve ROS dissolution, bioavailability, and therapeutic efficacy.
This approach offers a promising avenue for the clinical management of dyslipidemia and type 2 diabetes mellitus.